The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Aminomux     disodium3-amino-1,1- bis(hydroxy-oxido...

Synonyms: AHPrBP, Aredia, CHEMBL676, S1311_Selleck, AG-G-01793, ...
This record was replaced with 4674.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Aminomux


Psychiatry related information on Aminomux


High impact information on Aminomux


Chemical compound and disease context of Aminomux


Biological context of Aminomux


Anatomical context of Aminomux


Associations of Aminomux with other chemical compounds


Gene context of Aminomux


Analytical, diagnostic and therapeutic context of Aminomux


  1. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J.F., Seaman, J., Knight, R.D. N. Engl. J. Med. (1996) [Pubmed]
  2. Pamidronate and metastatic breast cancer. Kao, G. N. Engl. J. Med. (1997) [Pubmed]
  3. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J., Knight, R.D. N. Engl. J. Med. (1996) [Pubmed]
  4. More on pamidronate in Langerhans'-cell histiocytosis. Brown, R.E. N. Engl. J. Med. (2001) [Pubmed]
  5. Pamidronate associated hallucinations. Foley-Nolan, D., Daly, M.J., Williams, D., Wasti, A., Martin, M. Ann. Rheum. Dis. (1992) [Pubmed]
  6. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Arikoski, P., Silverwood, B., Tillmann, V., Bishop, N.J. Bone (2004) [Pubmed]
  7. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. Smith, M.R., McGovern, F.J., Zietman, A.L., Fallon, M.A., Hayden, D.L., Schoenfeld, D.A., Kantoff, P.W., Finkelstein, J.S. N. Engl. J. Med. (2001) [Pubmed]
  8. Gamma/delta T-cell stimulation by pamidronate. Kunzmann, V., Bauer, E., Wilhelm, M. N. Engl. J. Med. (1999) [Pubmed]
  9. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. Glorieux, F.H., Bishop, N.J., Plotkin, H., Chabot, G., Lanoue, G., Travers, R. N. Engl. J. Med. (1998) [Pubmed]
  10. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Gurney, H., Grill, V., Martin, T.J. Lancet (1993) [Pubmed]
  11. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H.D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., Seaman, J. J. Clin. Oncol. (2001) [Pubmed]
  12. Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. Montalvetti, A., Fernandez, A., Sanders, J.M., Ghosh, S., Van Brussel, E., Oldfield, E., Docampo, R. J. Biol. Chem. (2003) [Pubmed]
  13. Selective Excision of Chain-terminating Nucleotides by HIV-1 Reverse Transcriptase with Phosphonoformate as Substrate. Cruchaga, C., Ansó, E., Rouzaut, A., Martínez-Irujo, J.J. J. Biol. Chem. (2006) [Pubmed]
  14. Pharmacokinetics of pamidronate in patients with bone metastases. Leyvraz, S., Hess, U., Flesch, G., Bauer, J., Hauffe, S., Ford, J.M., Burckhardt, P. J. Natl. Cancer Inst. (1992) [Pubmed]
  15. Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases. Pelger, R.C., Lycklama à Nijeholt, A.A., Papapoulos, S.E. Lancet (1989) [Pubmed]
  16. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Reinholz, G.G., Getz, B., Pederson, L., Sanders, E.S., Subramaniam, M., Ingle, J.N., Spelsberg, T.C. Cancer Res. (2000) [Pubmed]
  17. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Lee, M.V., Fong, E.M., Singer, F.R., Guenette, R.S. Cancer Res. (2001) [Pubmed]
  18. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. Rauch, F., Travers, R., Plotkin, H., Glorieux, F.H. J. Clin. Invest. (2002) [Pubmed]
  19. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Kunzmann, V., Bauer, E., Feurle, J., Weissinger, F., Tony, H.P., Wilhelm, M. Blood (2000) [Pubmed]
  20. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. Girlanda, S., Fortis, C., Belloni, D., Ferrero, E., Ticozzi, P., Sciorati, C., Tresoldi, M., Vicari, A., Spies, T., Groh, V., Caligaris-Cappio, F., Ferrarini, M. Cancer Res. (2005) [Pubmed]
  21. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Ralston, S.H., Gallacher, S.J., Patel, U., Dryburgh, F.J., Fraser, W.D., Cowan, R.A., Boyle, I.T. Lancet (1989) [Pubmed]
  22. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Berenson, J.R., Hillner, B.E., Kyle, R.A., Anderson, K., Lipton, A., Yee, G.C., Biermann, J.S. J. Clin. Oncol. (2002) [Pubmed]
  23. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. Gutteridge, D.H., Ward, L.C., Stewart, G.O., Retallack, R.W., Will, R.K., Prince, R.L., Criddle, A., Bhagat, C.I., Stuckey, B.G., Price, R.I., Kent, G.N., Faulkner, D.L., Geelhoed, E., Gan, S.K., Vasikaran, S. J. Bone Miner. Res. (1999) [Pubmed]
  24. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. Pecherstorfer, M., Jilch, R., Sauty, A., Horn, E., Keck, A.V., Zimmer-Roth, I., Thiebaud, D. J. Bone Miner. Res. (2000) [Pubmed]
  25. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Hughes, D.E., Wright, K.R., Uy, H.L., Sasaki, A., Yoneda, T., Roodman, G.D., Mundy, G.R., Boyce, B.F. J. Bone Miner. Res. (1995) [Pubmed]
  26. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Redlich, K., Hayer, S., Maier, A., Dunstan, C.R., Tohidast-Akrad, M., Lang, S., Türk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., Kollias, G., Steiner, G., Smolen, J.S., Schett, G. Arthritis Rheum. (2002) [Pubmed]
  27. Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. Takagi, K., Takagi, M., Kanangat, S., Warrington, K.J., Shigemitsu, H., Postlethwaite, A.E. J. Immunol. (2005) [Pubmed]
  28. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. Conti, L., Casetti, R., Cardone, M., Varano, B., Martino, A., Belardelli, F., Poccia, F., Gessani, S. J. Immunol. (2005) [Pubmed]
  29. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Santini, D., Vincenzi, B., Avvisati, G., Dicuonzo, G., Battistoni, F., Gavasci, M., Salerno, A., Denaro, V., Tonini, G. Clin. Cancer Res. (2002) [Pubmed]
  30. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H.L., Capparelli, C., Starnes, C., Weimann, B., Dunstan, C.R., Kostenuik, P.J. Endocrinology (2005) [Pubmed]
  31. Palliative pamidronate treatment in patients with bone metastases from breast cancer. van Holten-Verzantvoort, A.T., Kroon, H.M., Bijvoet, O.L., Cleton, F.J., Beex, L.V., Blijham, G., Hermans, J., Neijt, J.P., Papapoulos, S.E., Sleeboom, H.P. J. Clin. Oncol. (1993) [Pubmed]
  32. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. Hortobagyi, G.N., Theriault, R.L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J.F., Seaman, J.J., Knight, R.D., Heffernan, M., Mellars, K., Reitsma, D.J. J. Clin. Oncol. (1998) [Pubmed]
  33. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Small, E.J., Smith, M.R., Seaman, J.J., Petrone, S., Kowalski, M.O. J. Clin. Oncol. (2003) [Pubmed]
WikiGenes - Universities